BMS 275183

BMS 275183 is a potent, orally active analogue of Paclitaxel (HY-B0015) . BMS 275183 can stabilize microtubules and exhibits antitumor activity in in vivo tumor models. BMS 275183 is active in vitro against Paclitaxel-resistant tumors including those harboring tubulin mutations or overexpressing P-glycoprotein. BMS 275183 can be used for cancer research, such as non-small cell lung cancer (NSCLC) and prostate carcinoma[1].

Product Specifications

CAS Number

[355113-98-3]

UNSPSC

12352005

Target

Microtubule/Tubulin; P-glycoprotein

Related Pathways

Cell Cycle/DNA Damage; Cytoskeleton; Membrane Transporter/Ion Channel

Field of Research

Cancer

Smiles

COC(O[C@]12[C@@]([C@]3([C@@H](O)C[C@@]1([H])OC2)C)([H])[C@@H]([C@]4(C(C)(C([C@@H](OC(C)=O)C3=O)=C(C)[C@@H](OC([C@H](O)[C@H](C(C)(C)C)NC(OC(C)(C)C)=O)=O)C4)C)O)OC(C5=CC=CC=C5)=O)=O

Molecular Formula

C43H59NO16

Molecular Weight

845.93

References & Citations

[1]Bröker LE, et al. Phase I trial with BMS-275183, a novel oral taxane with promising antitumor activity. Clin Cancer Res. 2006 Mar 15;12 (6) :1760-7.